Geneius Biotechnology is pioneering the development of personalized targeted T cell therapies aimed at treating various cancers. Their focus is on autologous, adoptive T-cell therapies, which utilize a patient's own T cells to elicit a stronger immune response against cancer compared to traditional methods. Clinical trials have demonstrated promising results, with a 70% overall response rate and a 50% complete response rate in patients with Epstein-Barr Virus (EBV)+ lymphoma. The company emphasizes the efficacy of their natural T cells in solid tumors, showcasing durable response rates and minimal side effects, primarily limited to mild flu-like symptoms. This approach is positioned as a more accessible and cost-effective alternative to CAR-T therapies, which have shown limited effectiveness in solid tumors and often require patients to be transferred to specialized cancer centers due to severe side effects.

In terms of their clinical pipeline, Geneius plans to submit an Investigational New Drug (IND) application to the US FDA within eight months of securing funding, with the potential for an initial public offering (IPO) shortly thereafter. They aim to gather data from clinical trials involving 70 patients, leveraging previous academic studies that indicated high efficacy and low toxicity. The company is optimistic that their manufacturing process will yield T cells that are as effective as those produced in earlier studies, thereby increasing the potential to treat a larger patient population compared to existing therapies like PD-1 inhibitors. Geneius's strategy reflects a commitment to advancing cancer treatment through innovative T cell therapies while maintaining a focus on patient accessibility and cost-effectiveness.

United States

Geneius Biotechnology, Inc. is a research company based out of 12 Michigan Dr, Natick, Massachusetts, United States.

Geneius Biotechnology

Company Details